Motor Neurone Disease Trial, Recruiting NCT06491732 Sponsor: Beth Israel Deaconess Medical Center Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06491732
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ALS (either in your family history or with no known family cause), confirmed by standard diagnostic guidelines
  • You are able to understand and agree to take part in the study, and can follow the study procedures as judged by the research team
  • Your ALS symptoms started no more than 36 months (3 years) ago
  • Your lungs are working at 40% or more of the expected capacity for a person your age and size
  • You have someone (such as a family member or caregiver) who can be present during home visits as part of the study
  • You have access to the internet, as some data will need to be uploaded
  • You are 18 years of age or older

Who may not be able to join:

  • You have another serious or unstable health condition (besides ALS) that could affect your ability to take part, as decided by the research team
  • You have been diagnosed with a condition called Primary Lateral Sclerosis (PLS), which only affects the upper part of the nervous system
  • You have a history of an unstable mental health condition, significant memory or thinking problems, dementia, or are currently misusing substances such as drugs or alcohol
  • You have noticeable fluid-related swelling in your body (called pitting edema, rated 2+ or higher) that could interfere with a specific type of measurement used in this study (confirm with trial site)
  • You currently have cancer, or you have previously been treated for cancer with chemotherapy or radiation therapy
  • Your Body Mass Index (BMI) — a measure of body weight relative to height — is above 35

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Seward Rutkove, MD, Beth Israel Deaconess Medical Center

Phone: 617-667-3056

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
30 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

EIM phase change over time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov